StreetInsider.com News Articles

Form 8-K RenovoRx, Inc. For: Jul 01

Thu, 02 Jul 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260702/26724368.html

Form 8-K RenovoRx, Inc. For: Jul 01

Thu, 02 Jul 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260702/26724368.html

Form S-8 RenovoRx, Inc.

Tue, 30 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260630/26714817.html

Form S-8 RenovoRx, Inc.

Tue, 30 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260630/26714817.html

Form 8-K RenovoRx, Inc. For: Jun 30

Tue, 30 Jun 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260630/26714537.html

Form 8-K RenovoRx, Inc. For: Jun 30

Tue, 30 Jun 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260630/26714537.html

Form 4 RenovoRx, Inc. For: Mar 03 Filed by: RYAN UNA S

Wed, 24 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260624/26686509.html

Form 4 RenovoRx, Inc. For: Mar 03 Filed by: RYAN UNA S

Wed, 24 Jun 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260624/26686509.html

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

Thu, 11 Jun 2026 08:30:00 -0400

PET-CT imaging, Rather than CT Alone, Presented a Meaningful Reduction in Tumor Metabolic Activity After Treatment, Suggesting that PET May Help to Optimize Therapeutic Response Monitoring Following Treatment Delivered via Trans-Arterial Micro-Perfusion (TAMP)

MOUNTAIN VIEW, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced the publication of a peer-reviewed case study from researchers at Moffitt Cancer Center was recently published in Radiology Case Reports.

The case study highlights potential optimization of

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

Thu, 11 Jun 2026 08:30:00 -0400

The case study highlights potential optimization of

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

Thu, 11 Jun 2026 08:30:00 -0400

The case study highlights potential optimization of

RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer

Thu, 11 Jun 2026 08:30:00 -0400

The case study highlights potential optimization of

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

Thu, 04 Jun 2026 08:30:00 -0400

MOUNTAIN VIEW, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer, Shaun Bagai, will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, being held June 23-24, 2026.

Mr. Bagai will present on Tuesday, June 23^rd at 12:30 P.M. ET. A replay will be available on the Company’s Investor Relations website after the event at https://ir.renovorx.com/news-events.

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

Thu, 04 Jun 2026 08:30:00 -0400

Mr. Bagai will present on Tuesday, June 23^rd at 12:30 P.M. ET. A replay will be available on the Company’s Investor Relations website after the event at https://ir.renovorx.com/news-events.

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

Thu, 04 Jun 2026 08:30:00 -0400

Mr. Bagai will present on Tuesday, June 23^rd at 12:30 P.M. ET. A replay will be available on the Company’s Investor Relations website after the event at https://ir.renovorx.com/news-events.

RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd

Thu, 04 Jun 2026 08:30:00 -0400

Mr. Bagai will present on Tuesday, June 23^rd at 12:30 P.M. ET. A replay will be available on the Company’s Investor Relations website after the event at https://ir.renovorx.com/news-events.

RenovoRx receives FDA orphan drug designation for oxaliplatin

Thu, 28 May 2026 08:31:28 -0400

RenovoRx Inc. (NASDAQ: RNXT) announced that the U.S. Food and Drug Administration granted orphan drug designation for oxaliplatin in treating pancreatic cancer, according to a company statement.

The designation was issued by the FDA's Office of Orphan Products Development under Section 526 of the Federal Food, Drug, and Cosmetic Act. Oxaliplatin is an approved chemotherapy drug commonly used in cancer treatment.

This marks RenovoRx's third orphan drug designation overall and second for pancreatic cancer. The company previously received designations for intra-arterial gemcitabine delivered via its RenovoCath device for locally advanced pancreatic cancer and bile duct cancer.

The orphan drug designation provides seven years

RenovoRx receives FDA orphan drug designation for oxaliplatin

Thu, 28 May 2026 08:31:28 -0400

RenovoRx Inc. (NASDAQ: RNXT) announced that the U.S. Food and Drug Administration granted orphan drug designation for oxaliplatin in treating pancreatic cancer, according to a company statement.

The orphan drug designation provides seven years

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

Thu, 28 May 2026 08:30:00 -0400

Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity

MOUNTAIN VIEW, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a novel, FDA-cleared drug-delivery device, today announced that the U.S. Food and Drug Administration (FDA) recently granted RenovoRx Orphan Drug Designation (ODD) of oxaliplatin for the treatment of pancreatic cancer.

The designation was issued by the FDA’s Office of Orphan Products Development pursuant to Section 526 of the

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

Thu, 28 May 2026 08:30:00 -0400

Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity

The designation was issued by the FDA’s Office of Orphan Products Development pursuant to Section 526 of the

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

Thu, 28 May 2026 08:30:00 -0400

Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity

The designation was issued by the FDA’s Office of Orphan Products Development pursuant to Section 526 of the

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

Thu, 28 May 2026 08:30:00 -0400

Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity

The designation was issued by the FDA’s Office of Orphan Products Development pursuant to Section 526 of the

RenovoRx presents pharmacokinetic data at ASCO meeting

Tue, 26 May 2026 08:32:12 -0400

RenovoRx Inc. (NASDAQ: RNXT) announced that pharmacokinetic data from a sub-study of its Phase III TIGeR-PaC clinical trial was published in connection with the 2026 American Society of Clinical Oncology Annual Meeting held May 29 through June 2 in Chicago.

The sub-study examined the company's TAMP platform for targeted intra-arterial delivery of gemcitabine via its RenovoCath device in locally advanced pancreatic cancer patients. The analysis involved 16 patients across six trial sites and compared intra-arterial gemcitabine administration with intravenous delivery.

Results showed that intra-arterial gemcitabine administration correlated with increased metabolite levels and reduced CA 19-9, a biomarker used to assess chemotherapy response.

RenovoRx presents pharmacokinetic data at ASCO meeting

Tue, 26 May 2026 08:32:12 -0400

Results showed that intra-arterial gemcitabine administration correlated with increased metabolite levels and reduced CA 19-9, a biomarker used to assess chemotherapy response.

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

Tue, 26 May 2026 08:30:00 -0400

Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects

MOUNTAIN VIEW, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced that an abstract from a pharmacokinetic (PK) and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial has been published online in connection with the